Francis Kynaston-Pearson: Why Randomised Controlled Trials Are the Gold Standard in Clinical Research
Francis Kynaston-Pearson, Consultant Rheumatologist at Mediclinic Middle East, shared a post on LinkedIn:
“The randomised control trial (RCT) – the ‘gold standard’ for clinical evidence.
If that is so, why is all evidence not gathered in such a manner.
For those in research, the answer is evident but doctors and scientists forget that the complexities of the nuts and bolts of a quality trial are not common knowledge of our patients.
Not all questions can be answered with an RCT, not to mention the cost in setting one up.
Trials with mild or moderate methodological failing or negative results may not even get published, with the hard work never known outside the investigating team.
For anyone who wanted a quick overview of RCTs but was a little afraid or embarrassed to ask, here is a quick video for you.”
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support
-
Apr 16, 2026, 09:09Naung Latt Htun: High Clinical Suspicion in Acquired Hemophilia A is Essential
-
Apr 16, 2026, 08:58Chittal Raulji: ASH-ISTH 2026 Guidelines for Anticoagulant Prophylaxis for Pediatric VTE Is Now Live in Blood Advances
-
Apr 16, 2026, 08:47Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP
-
Apr 16, 2026, 08:19M Rafiqul Islam: Post-Thrombectomy Blood Pressure Management in Acute Ischemic Stroke
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery